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SUMMARY 
 
Emerging evidence supports the concept that biochemical markers are clinically 
useful as non invasive diagnostic tools for the monitoring of changes in bone and cartilage 
turnover in subjects affected by pathologies with destructive bone and joint diseases such 
as osteoporosis, osteoarthritis, rheumatoid arthritis and osteosarcoma. Epidemiological 
studies demonstrated that the measurements of different bone degradation products in urine 
or serum samples are higher in patients affected by the above reported pathologies 
compared with healthy subjects. 
Among the different biochemical markers used for clinical purpose, the changing in urine 
concentrations of pyridinium crosslinks is usually measured. Pyridinium crosslinks are 
generally referred to the chemical compounds pyridinoline (Pyr) and deoxypyridinoline 
(D-Pyr), both considered specific markers of skeletal collagen degradation. They are 
released into the circulation during bone resorption as small peptides that can be further 
degradated into free crosslinks in kidney and excreted in urine in both free and peptides or 
sugars bound forms as the disaccharide glucose-galactose Pyr (GluGal-Pyr) and the 
monosaccharide galactose Pyr (Gal-Pyr), both formed from a post-translation modification 
of collagen. The first sugar bound form, reported absent in bone by some authors, is 
considered an important predictor of joint tissue degradation, whereas for the second one, 
mainly present in bone, no specific role has been found and it has never been measured.  
Commonly, only the total Pyr and D-Pyr (free+bound forms) amounts, obtained from urine 
submitted to overnight acid hydrolysis, are measured as markers of bone resorption by 
high-performance liquid chromatography (HPLC) coupled to a fluorescence detector. 
However, the variability of literature results, depending on analytical problems (hydrolysis, 
solide-phase purification, recovery) and physiological factors (age, gender) renders the 
results from different analytical laboratories difficult to be compared. Moreover, results 
obtained from different analytical methods are often compromised by the lack of an 
adequate internal standard allowing to eliminate errors occurring during sample 
preparation and analytical measurement.  
In spite of extensive literature, important points for crosslinks measurement have not been 
solved:  
1) the choice of an adequate internal standard, required by many researchers working in 
this field, that allows the specificity of the analytical method and avoids errors 
occurring during all the pre-analytical steps; 
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2) the pure authentic reference standards, obtained by synthesis, to be used as primary 
calibrators necessary to improve the crosslinks quantification process; 
3) the evaluation of crosslinks in their total (free + bound forms) and/or free forms. In fact 
the assessment of total urinary D-Pyr, found only in bone and dentine, provides an 
index of bone resorption whereas the evaluation of total Pyr does not allow to 
distinguish among the degradation of bone, synovium and joint and between free and 
glycosylated-Pyr. 
The aim of the present study was to develop and validate an HPLC-fluorescence method 
for the measurement of Pyr and D-Pyr in free, glycosylated and total forms in healthy 
women and in children urine. Women were selected to compare our results with those 
reported by others in adult healthy groups. Children were enrolled as, being in growing age 
and having an extremely high remodelling rate, their physiological levels of urine collagen 
crosslinks in this stage of the life appeared of particular interest to be compared with those 
of an omogeneous group of pre-menopauseal women. Moreover, studies on children were 
performed in order to estimate GluGal-Pyr and Gal-Pyr amounts as these glycosylated 
pyridinolines have never been measured until now. 
The specificity of the method was assured by a synthesized superior homologue of D-Pyr, 
here proposed as internal standard (IS) for the first time, added to the biological samples 
before any pre-analytical step. Moreover, pure synthesized Pyr, D-Pyr, Gal-Pyr and 
GluGal-Pyr were used as primary calibrators for the correct HPLC identification of each 
analyte by their corresponding retention times and for their accurate quantification by 
specific calibration curves. 
To validate the method for the measurement of all the crosslinks of interest, various 
analytical performance parameters (linearity, recovery, within and between-day 
repeatabilities, reproducibility, limit of detection, limit of quantitation) have been 
considered and here reported. 
The results demonstrate, for the validated method, good linearity, recovery, precision, limit 
of detection and limit of quantitation for all compounds. 
The measurement of consisting amounts of GluGal-Pyr in both women and children urine 
and few but detectable Gal-Pyr amounts only in children confirm the importance for free 
and glycosylated crosslinks quantification. In fact, only the evaluation of free glycosylated 
and total crosslinks excretion can provide more information on different collagen 
catabolism, since total crosslinks amounts give no information on the intermediate 
products (pyridinoline glycosides) generated by various collagen degradations. 
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INTRODUCTION 
 
Bone formation and matrix components 
Bone is a living and dynamic tissue formed by cells (osteoclasts and osteoblasts) 
surrounded by an extracellular calcified amorphous matrix containing fibers and 
glycoproteins. The calcifying mineral compound [hydroxyapatite; Ca10(PO4)6(OH)2] 
confers hardness and mechanic resistance to bone, whereas fibers affect the flexibility. 
Bone undergoes two opposing processes determining the bone density, i.e bone formation 
(by osteoblasts) and bone resorption (by osteoclasts).  
Osteoblasts, under the control of osteoclasts, synthesize in the endoplasmic reticulum both 
fibers and glycoproteins of the amorphous matrix, but the final matrix chemical structure is 
completed out of cells (1). Alkaline phosphatase, an enzyme able to split the phosphoric 
bounds of pyrophosphate, a physiological inhibitor of bone formation, is active in 
osteoblasts with specific membrane’s receptors for estrogens. On the contrary, an acidic 
phosphatase enzyme, able to destroy the bone calcified matrix, is present in osteoclasts 
with specific membrane’s receptors for parathyroid hormone.  
During youth, the osteoblasts activity is higher than the osteoclasts one, during the middle-
age the two processes are in equilibrium, whereas in the old-age the bone resorption is 
greater than bone formation. About 90% of total adult bone mass is accrued by age 20, and 
a significant proportion of this is achieved only during puberty (2). 
Collagen and elastine are the components of the fibrous bone extracellular matrix. 
Collagen, the most abundant protein in the human body, constitutes approximately 30% of 
the body proteins, with up to 40% in skin and 50% in bone. Tropocollagen, the structural 
unit of collagen, is formed by three similar or different α-polypeptide chains linked by 
hydrogen bounds and with amino- and carboxyl- terminal groups. After their synthesis in 
the endoplasmic reticulum, the three tropocollagen subunits associate to build a right-
handed triple helix. However, before this step, the nascent collagen polypeptide undergoes 
several post-translational modifications, comprising the enzymatic hydroxylation of 
proline and lysine residues by hydroxylases. Collagen is characterized by domains 
representing repeats of the triplet Gly-X-Y, where proline and lysine are often found at 
positions X and Y; approximately 100 proline and 10 lysine residues are present in every 
chain (3,4).  
Hydroxyproline and hydroxylysine contribute to the stability of the collagen triple helix, 
where hydroxylysine is essential for the crosslinking of collagen molecules, ensuring the 
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strength of collagen fibrils. Hydroxylysine and hydroxyproline can be further modified by 
reaction with the specific β(1-O) galactosyl and α(1-2) glucosyl transferase, enzymes 
forming the glycosylated derivatives galactose-hydroxylysine and glucose-galactose 
hydroxylysine (5). In these two glycosylated derivatives, glucose and galactose are linked 
by β-glycosidic bonds to the hydroxyl groups of hydroxylysine residues. After the 
hydroxylation reactions, three pro-alpha chains fold together and procollagen molecules 
are excreted by the cells into extracellular space where the two non-helical extensions, 
called N- and C-terminal procollagen peptides are cleaved off by two specific peptidases 
(6). 
The importance of post-translational modifications of collagen is reflected in diseases 
caused by defective collagen modifying enzymes giving a deglycosylated collagen form. 
Mutations of the lysyl hydrolase lead to connective tissue disorders (7-9).  
 
 
Collagen crosslinks 
After the release from bone cells in the extracellular matrix, collagen molecules are 
stabilized by crosslinking aminoacids generating different bounds inside and among 
collagen molecules (10).  
The intramolecular crosslinks, in which two α chains within the same molecule may be 
covalently linked, are mainly bifunctional. They are present in newly formed collagen and 
are also called reduced crosslinks as they may be analitically investigated by mild chemical 
reduction utilizing borohydride. The integrity and the physical-chemical properties of bone 
are depending on these bounds between adjacent collagen fibrils. For fibrous collagen, 
these bonds are conferring a very high tensile strength.  
The intermolecular crosslinks, involving the formation of covalent bridges between chains 
in different molecules, are mainly trifunctional. They are present in mature tissue and 
cannot be reduced (they are referred as non-reducible mature crosslinks). These covalent 
crosslinks of collagen molecules begin with the COOH-terminal non α-helical region and 
this step may occur before intramolecular crosslinking formation (11) (Fig.1). 
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Fig.1 Schematic rapresentation of the location of immature and mature enzymatic 
crosslinks 
 
 
 
 
(a) Immature, bivalent crosslinks within microfibrils (b) Mature microfibrils illustrating the 
interfibrillar linkage of collagen molecules in parallel allignment 
 
 
 
To date, about 29 types of collagen have been identified and described, which are 
encoded by at least 44 genes (5,9) and are characterized by different -chains bounded 
together. Depending on the collagen type, the three  chains can be either identical or the 
molecule can contain two or even three different  chains. Type I collagen is formed by 
two chains 1 and one chain 2, whereas Type II collagen is formed by three chains 1. 
Type I is ubiquitously distributed and forms the major protein in skin, bone, tendon, 
ligament, sclera, cornea, blood vessels but some collagens have a districted tissue 
distribution: for example, as Type II, IX and XI found almost exclusively in cartilage and 
Type X, found only in hypertrophic and mineralizing cartilage. (Tab. 1) 
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Tab. 1 Types of collagen and associated disorders 
 
 
Type Notes (location) Gene(s) Disorders 
I This is the most abundant collagen of the 
human body. It is present in scar tissue, the 
end product when tissue heals by repair. It is 
found in tendons, skin, artery walls, the 
endomysium of myofibrils, fibrocartilage, and 
the organic part of bones and teeth. 
COL1A1 
COL1A2 
osteogenesis 
imperfecta, Ehlers-
Danlos Syndrome, 
Infantile cortical 
hyperostosis aka 
Caffey's disease 
II Hyaline cartilage, makes up 50% of all 
cartilage protein. Vitreous humour of the eye. 
COL2A1 Collagenopathy, types 
II and XI 
III This is the collagen of granulation tissue, and 
is produced quickly by young fibroblasts 
before the tougher type I collagen is 
synthesized. Reticular fiber. Also found in 
artery walls, skin, intestines and the uterus 
COL3A1 Ehlers-Danlos 
Syndrome 
IV basal lamina; eye lens. Also serves as part of 
the filtration system in capillaries and the 
glomeruli of nephron in the kidney. 
COL4A1 
COL4A2 
COL4A3 
COL4A4 
COL4A5 
COL4A6 
Alport syndrome, 
Goodpasture's 
syndrome 
V most interstitial tissue, assoc. with type I, 
associated with placenta  
COL6A1 
COL6A2 
COL6A3 
Ehlers-Danlos 
syndrome (Classical) 
VI most interstitial tissue, assoc. with type I COL6A1 
COL6A2 
COL6A3 
Ulrich myopathy and 
Bethlem myopathy 
VII forms anchoring fibrils in dermal epidermal 
junctions 
COL7A1 epidermolysis bullosa 
dystrophica 
VIII some endothelial cells COL8A1 
COL8A2 
Posterior 
polymorphous corneal 
dystrophy 2 
IX FACIT collagen*, cartilage, assoc. with type II 
and XI fibrils 
COL9A1 
COL9A2 
COL9A3 
EDM2 and EDM3 
X hypertrophic and mineralizing cartilage COL10A1 Schmid metaphyseal 
dysplasia 
XI Cartilage COL11A1 
COL11A2 
Collagenopathy, types 
II and XI 
 
* FACIT collagen: Fibril Associated Collagens with Interrupted Triple helices. 
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Physiological and pathological bone resorption     
Bone mass may be influenced by several factors that can be grouped into factors 
that cannot be modified, such as gender, age, genetics and ethnicity, and those that can be 
modified, as lifestyle including physical activity levels, smoking, alcohol consumption and 
diet (12). Under physiological conditions, extracellular matrix production balances the 
breakdown, thereby ensuring the continuous renewal of this critical tissue component. 
When the bone formation cannot keep up with the degradation processes, a loss of the 
structural integrity of bone and/or cartilage emerges as a net result (10). From this 
unbalance, the skeletal fragility can result due to: (a) a failure to produce a skeleton of 
optimal mass and strength during growth; (b) an excessive bone resorption resulting in 
decreased bone mass and microarchitectural deterioration of the skeleton; and (c) an 
inadequate formation response to increased resorption during bone remodelling. The high 
rates of resorption are not always associated with bone loss, for example, during the 
pubertal growth.   
Drastic bone and/or cartilage resorptions have been observed and studied in pathological 
conditions such as osteoporosis, osteoarthritis, rheumatoid arthritis, osteosarcoma and joint 
desease (13-17). The first three diseases are shortly described below. 
Osteoporosis is a global health problem that will take on increasing significance as people 
live longer and the world’s population continues to increase. Moreover, it is also a socio-
economic problem because long-term therapy is needed to prevent fractures and chronic 
disability. Osteoporosis is defined as a systemic skeletal disease characterized by low bone 
mass and microarchitectural deterioration of bone tissue, with a consequent increase in 
bone fragility and susceptibility to fracture particularly common in the spine, hip, and 
distal forearm (14).  
Rheumatoid arthritis and osteoarthritis are severe chronic debilitating diseases with 
articular cartilage destruction, loss of periferal joint function and consequent pain, 
impaired mobility and disability. Rheumatoid arthritis is an autoimmune disease with 
chronic inflammation of the joints characterized by an influx of inflammatory cells like 
monocytes, macrophages and fibroblasts into the synovial fluid with subsequent release of 
pro-inflammatory agents and induction of cartilage degradation through activation of 
different proteases (16,17). Osteoarthritis, a prevalent age-related disease with a strong 
genetic component, is characterized by progressive destruction of articular cartilage.  
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Markers of bone turnover for clinical investigations. 
  Clinical information on bone health and/or skeletal diseases and the monitoring of 
the response to pharmacological treatments are achieved measuring specific markers of 
bone turnover in serum or in urine samples. Usually, these markers are the following: 
- Bone formation markers: 
1) Serum alkaline phosphatase: active enzyme in osteoblasts, ables to split the 
phosphoric bounds of pyrophosphate, a physiological inhibitor of bone formation. 
This enzyme originates from various tissues, such as liver, bone, intestine and 
kidney. Its enzymatic activity is measured by radioimmunological or immunoassay 
methods with monoclonal antibodies.  
2) Serum osteocalcin: non collagenic small protein (49 amino acids) synthesized by 
osteoblasts and incorporated into the extracellular matrix. It is known as bone Gla-
protein because it contains three vitamin-K-dependent γ-carboxyglutamic acid 
(Gla) residues which serve as calcium binding sites and may be involved in bone 
mineralization.  
3) Serum procollagen type 1 propeptides: procollagen type 1 contains N- and C-
terminal extensions, (called P1NP and P1CP, respectively), which are removed by 
specific proteases during the extracellular conversion of procollagen to collagen. 
During bone resorption, these short fragments, still crosslinked through Pyr and D-
Pyr and called telopeptides, are cleaved by osteoclasts and enter the circulation. 
Radioimmunological or immunoassay methods are used for their evaluation.   
 - Bone resorption markers: 
1) Acidic phosphatase: active enzyme in osteoclasts ables to destroy the bone calcified 
matrix.  
2) Measurement of urine calcium concentration.  
3) Urinary hydroxyproline: this aminoacid represents 13% of the total collagen 
aminoacids and is released in serum and urine in free and bound forms.  
4) Pyridinium crosslinks:  pyridinoline (Pyr) and deoxypyridinoline (D-Pyr) form 
covalent crosslink bonds among adjacent collagen chains stabilizing the 
extracellular matrix.   
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Markers for bone resorption: pyridinium crosslinks 
The pyridinium crosslinks, known as pyridinoline (Pyr: hydroxylysyl-pyridinoline) 
and deoxy- pyridinoline (D-Pyr: lysyl-pyridinoline) (Fig.2), are the main non-reducible 
fluorescent trifunctional crosslinks in mature skeletal tissues.   
 
 
 
Fig.2 Pyr and D-Pyr structural formulas 
 
 
 
 
 
 
Pyridinoline is formed by the reaction of two hydroxyallysines with an hydroxylysine 
residue, while deoxypyridinoline by the reaction of two hydroxyallysines and a lysine 
residue. 
Several non-enzymatic mechanisms have been proposed for Pyr and D-Pyr biosynthesis; a 
reaction between two hydroxyallysine and one hydroxylysine residue or an aldol 
condensation of hydroxyallysine with a divalent crosslink followed by an intramolecular 
condensation (10,18) (Fig.3). 
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Fig.3  Intramolecular aldol condensation 
 
 
 
As a consequence of bone resorption, both Pyr and D-Pyr are released into the circulation 
as small peptides that can be further degradated into free crosslinks in kidney and excreted 
in urine in both free (~ 40%) and peptides or sugars bound forms (~ 60%) (14,19,20-22). 
They are widely accepted as specific markers of skeletal collagen degradation (22-27), as 
they are not reused for new collagen synthesis or metabolized in the liver. Pyridinoline, the 
most abundant, has been found in bone, cartilage, tendon, and some other connective 
tissues, but not in skin (19). On the contrary D-Pyr is almost exclusively present in bone 
and dentine where its concentration is about one fourth of that of Pyr (19).  
Some studies involved as degradation markers also two Pyr analogues deriving from post-
translational modification of collagen: glucose-galactose Pyr (GluGal-Pyr) and the 
galactose Pyr (Gal-Pyr) (18,21,22,27-32) (Fig.4). 
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Fig.4.  Glucose-galactose-Pyr and galactose-Pyr chemical structures 
 
 
 
 
As reported in Table 2, both Pyr and D-Pyr have been found in bone (Type I collagen), Pyr 
in cartilage (Type II collagen), Pyr and GluGal-Pyr in synovium (Type III collagen) 
(29,33), whereas Gal-Pyr mainly in bone (31). GluGal-Pyr is considered an important 
predictor of joint tissue degradation being found associated with pain and physical function 
and increased in urine of patients with osteoarthritis (19) and in synovial tissue (31), but is 
absent from bone tissue (31,32). In patients with early rheumatoid arthritis, a 70-100% 
increase of GluGal-Pyr in urine was observed respect to healthy controls (32). As concern 
Gal-Pyr, its presence in synovium and bone has only been observed in HPLC 
chromatograms, but its concentration has never been measured (32).  
 
 
Tab.2 Pyridinium crosslinks markers of bone, cartilage and synovium turnover 
 
Tissue (Collagen) Degradation Compounds 
Bone (Type I) Pyr + D-Pyr + Gal-Pyr 
Cartilage (Type II ) Pyr 
Synovium (Type III) Pyr + GluGal-Pyr 
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The molar ratio of Pyr to D-Pyr in urine is very similar to that found in bone (19,20) 
indicating that both Pyr and D-Pyr are derived mainly from bone. However, D-Pyr would 
be a more appropriate bone marker respect to Pyr for patients with cartilage disease (e.g. 
rheumatoid arthritis) who have a significant increase in Pyr from non-bone tissue. Some 
variables such as age, gender, ethnicity and body mass index may influence background 
levels of these biomarkers. Moreover, levels of the bone turnover markers are influenced 
by a marked circadian variation (34), whereas cartilage markers show little diurnal 
variability (13).  
Among compounds forming crosslink bounds, there are also hydroxyproline and 
hydroxylysine that, as Pyr and D-Pyr, are excreted in urine after bone resorption as free or 
glycosylated (linked with glucose or glucose-galactose). However, hydroxyproline cannot 
be considered as a specific marker of collagen breakdown since it derives from both the 
degradation of newly synthesized collagens originated from different tissues other than 
bone and the diet. Moreover, most of the free hydroxyproline amount is further 
metabolized to other products; thus only a fraction of the totally produced hydroxyproline 
is recovered in urine (4,35). Regarding hydroxylysine, studies reported its higher 
concentration in skin than in bone, therefore this compound is thought to reflect skin 
collagen metabolism rather than bone metabolism (6,35,36). However, hydroxylysine and 
its glucose-galactose conjugated compound are commonly measured in children and 
adolescents urine to have clinical information on their skeletal health (35-38). 
 
Analytical methods for pyridinium crosslinks measurement 
Usually, the analytical procedures submit urine to an overnight acid hydrolysis, 
allowing the evaluation of total Pyr and D-Pyr (15,28,34,41,42), whereas only few authors 
quantified free urinary pyridinolines amounts (16,27,39,40). 
Currently, high-performance liquid chromatography (HPLC) coupled to a fluorescence 
detector is a valid analytical method allowing the separation of Pyr and D-Pyr for 
quantitative determinations. This measurement takes advantage of fluorescent properties of 
these compounds but is a time-consuming method requiring extensive sample pre-
treatment and purification steps before the HPLC analysis. Thus, for routine use, simple 
and less expensive immunoassays have been developed to measure urinary Pyr and D-Pyr. 
Commercially available methods include enzyme immune assays (EIA) specific for free 
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Pyr and D-Pyr, and radioimmuno assays (RIA) for total or free D-Pyr (25,39,41,43,44). D-
Pyr is also measured by chemiluminescence immunoassay. 
 
Requirements necessary for quantitative measurements of biological analytes: importance 
of the internal standard and of pure primary calibrators 
The specificity of the existing analytical methods for the crosslinks evaluation is 
often compromised  by the lack of an adequate internal standard and of pure synthesized 
primary calibrators, in particular for the glycosylated compounds. The internal standard is 
necessary to avoid errors occurring during all the pre-analytical steps (hydrolysis, solid-
phase purification), whereas the primary calibrators are necessary to improve the analytes 
quantification process.  
Thus, the variability of literature results on urine crosslinks amounts, depending also from 
physiological factors (age, gender) (26,34), renders the results from different analytical 
laboratories difficult to be compared (25,26,41). 
Generally, an ideal internal standard has to be an analog of the target compound exibiting 
physico-chemical properties virtually identical and must be added in known amounts to the 
biological sample before any pre-analytical step. Moreover, it should be clearly resolved 
from the analyte that has to be measured, recovered from any extraction procedure in the 
same fraction as the analyte, stable under the assay conditions employed and absent in the 
biological matrix. Thus, being the partition coefficient for the standard and the analyte the 
same, any potential error caused by an inefficient and/or variable procedure is avoided and 
the ratio of metabolite to internal standard is unmodified during all the analytical 
procedures. Therefore, the use of an adequate internal standard guarantees good precision, 
specificity and reproducibility for the method, since it reduces problems of extraction 
recovery and biological matrix effects. 
The need of an internal standard for pyridinium crosslinks measurement has been 
underlined by many authors (22,25-27,39). Moreover, as no reference standards of the 
compounds of interest are available, every laboratory performing crosslinks measurements 
use different compounds or primary calibrators, such as Pyr or D-Pyr, often isolated and 
prepared by each laboratory from various sources, including animal or human.  
In attempt to search for a compounds useful as internal standard for crosslinks 
measurement, isodesmosine, propylated or acetylated pyridinoline and pyridoxine have 
been proposed as internal standards for crosslinks measurement (16,22,26,27,39,45). 
Isodesmosine, an elastine crosslink, is not suitable as an internal standard being 
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endogenously present in urine and recovered in the same extraction fraction as the 
crosslinks (46). Propylated and acetylated pyridinolines themselves hydrolyzed under 
acidic conditions, cannot be used for Pyr and D-Pyr total amounts evaluation, but 
eventually only for their free forms (16,45). Pyridoxine (Vitamine B6) is not suitable 
having a different chromatographic behaviour than the crosslinks. Pyridoxine has been also 
used as an external calibrator, added to biological samples after the hydrolysis reaction 
(24,27). Recently, an internal standard unknown from a chemical point of view to the 
authors as not specified by the factory (proprietary information), was used for total 
crosslinks evaluation by an automated HPLC method (42).  
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AIM OF THE STUDY 
 
In spite of extensive literature on the crosslinks evaluation, some major points have still 
not been solved: 
1) the choice of an adequate internal standard for the quantitative crosslinks measurement, 
required by many researchers working in this issue; 
2) the pure authentic reference standards, obtained by synthesis, to be used as primary 
calibrators necessary to improve the crosslinks quantification process; 
3) the evaluation of crosslinks in their total (free + bound forms) and/or free forms.  
In fact, the assessment of total urinary D-Pyr, found only in bone and dentine (19), 
provides an index of bone resorption, whereas the evaluation of total Pyr does not allow to 
distinguish between bone, synovium and joint degradation and between free and 
glycosylated-Pyr.  
In view of the above, the aim of the present study was to develop and validate an HPLC-
fluorescence method for the quantification of both Pyr and D-Pyr in their free and total 
forms, together with Gal-Pyr and GluGal-Pyr in urine of healthy women and children. The 
specificity of the method was allowed by the use of a synthesized superior homologue of 
D-Pyr, having one carbon longer lysine side chain at the eterocyclic nitrogen, here 
proposed as internal standard (IS) for the first time (Fig. 5). The internal standard is added 
to the biological samples before any pre-analytical steps. Pure synthesized Pyr, D-Pyr, Gal-
Pyr and GluGal-Pyr were used as primary calibrators for both the correct HPLC 
identification and quantification of each analyte by their corresponding calibration curves.  
 
 
Fig.5. Chemical structure of the internal standard.  
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MATERIALS AND METHODS 
 
Chemicals and Reagents 
Methanol and acetonitrile (HPLC-grade), hydrochloric acid (37%), acetic acid, 
heptafluorobutyric acid (HFBA) and pentafluoropropionic acid (PFPA) were purchased 
from Sigma-Aldrich-Chemie GmbH (Steinheim, Germany). Microgranular cellulose 
powder (CC31 type) was from Whatman Inc (NJ, USA). Empty SPE columns (12 mL) 
with 20-μm frits and ReproSil-Pur Basic RP C18 column (200 x 3 mm, 5 m) were from 
Maisch GmbH (Ammerbuch, Germany). RP Nucleosil 100 C18 column (200 x 2.1 mm, 5 
m) was from Teknokroma (S. Coop. C. Ltda, Barcelona). Both analytical columns were 
protected by a guard column ReproSil-Pur Basic C18 (10x3 mm, 5 m) from Maisch 
GMBH (Ammerbuch, Germany). SPE vacuum manifold was from J.T. Baker (NJ; USA).  
 
 
Primary calibrators and Internal standard 
Pyr, D-Pyr, GluGal-Pyr, Gal-Pyr and IS were synthesized, purified and chemically 
characterized by Nuclear Magnetic Resonance (NMR) and Mass Spectrometry as 
previously reported (47-53) by Prof. Mario Anastasia and Prof. Pietro Allevi (Dipartimento 
di Chimica, Biochimica e Biotecnologie per la Medicina, Facoltà di Medicina e Chirurgia, 
Università degli Studi di Milano). For their chemical structures see Fig.2, 4 and 5. 
The molar absorption coefficients (ε= L mol-1 cm-1) in HCl 0.1 mol/L at 295 nm (λmax ) 
were: 6520 (Pyr), 6480 (D-Pyr), 6400 (Glugal-Pyr and Gal-Pyr) and 6490 (IS). 
 
 
Instrument and HPLC analysis 
The HPLC system included a LC pump 200 system (Perkin Elmer, U.K.) equipped 
with a Perkin Elmer LC 240 fluorescence detector with xenon lamp (Perkin Elmer, U.K.). 
Data were integrated using Turbo Chrom Navigator connected with an interface NCI 900 
series (Perkin Elmer, U.K.). 
Two HPLC columns were tested: 1) Nucleosil 100 RP C18 and 2) ReproSil-Pur Basic C18. 
Various mobile phases added with ion-pairing agents as pentafluoropropionic acid (PFPA) 
or heptafluorobutyric acid (HFBA), were compared (22,23,39). Firstly, we tested an 
aqueous PFPA solution (0.009 mol/L) as mobile phase at 0.4, 0.5, 0.6 mL/min flow rate 
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but no adequate separation of all the peaks was reached. No better results were obtained 
using as mobile phase an aqueous PFPA solution (0.009 mol/L) in H2O:ACN (90:10, 95:5, 
98:2) as GluGal-Pyr, Gal-Pyr and Pyr peaks were overlapped or IS and D-Pyr peaks not 
well resolved or too long retention time were observed. Even the use of aqueous PFPA 
solution (0.009 mol/L) in H2O:MeOH (97:3) at 0.2 or 0.6 mL/min as flow rate did not 
improve the peaks resolution. 
The best HPLC crosslinks resolution was obtained in isocratic assay using ReproSil-Pur 
Basic C18 column with aqueous HFBA solution (0.015 mol/L): acetonitrile (88:12) as 
mobile phase at 0.6 mL/min flow rate with the fluorescence detector set at λex 295 nm and 
λem 400 nm. The total runtime for each analysis was 35 min.   
The identification of all peaks was made by the absolute retention times of the 
corresponding pure synthesized crosslinks. Every 3-4 samples injected, the column was 
washed with acetonitrile and reconditioned with the mobile phase. Each analyte was 
quantified using its calibration curve. 
 
 
Standard and Working Solutions 
Standard stock solutions were prepared by dissolving weighed pure standards 
amounts in 0.1 mol/L HCl, aliquoted and stored at –20°C. The final concentrations, 
confirmed reading the absorbance values were: D-Pyr (9.50x10
-5
 mol/L), Pyr (1.20x10
-4
 
mol/L), GluGal-Pyr (1.06x10
-4
 mol/L), Gal-Pyr (2.04x10
-4
 mol/L) and IS (1.20x10
-4
 
mol/L). 
Working standard solutions were prepared by diluting the standard stock solutions with 
aqueous HFBA solution (0.015 mol/L), aliquoted and stored at -20°C until use. The final 
working solutions concentrations were: D-Pyr and Pyr (26.60 μmol/L), GluGal-Pyr (26.62 
μmol/L), Gal-Pyr (26.75 μmol/L) and IS (26.67 μmol/L).   
 
 
Subjects and urine collection 
Twenty healthy women volunteers (n=20, 33.9±7.1 years) and twenty girls (n=10; 5.8±0.8 
years, n=10; 9.6±0.5 years), all in good general health, were included in this study. 
Informed consent was obtained from the subjects themselves or parents, respectively. All 
subjects had no history of metabolic bone diseases and all pre-menopausal women were 
receiving no medications affecting calcium absorption and metabolism. 
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Fasting first-time urine was collected in the morning, aliquoted and stored at -40°C until 
analysis. Urines from healthy women (n=7; 35.6±7.6 years) were pooled, aliquoted, stored 
at -40°C and used for urine calibration curves preparation and for studying the hydrolysis 
reaction.  
 
 
Free and glycosylated crosslinks extraction from urine 
Different reported conditions for urine crosslinks purification by solid phase 
extraction (SPE) were compared (23,39). The following variables were tested: 
-Cellulose amount for SPE column: 100, 400, 800 mg 
-Washing solution to elute urine interfering compounds :  
1) acetonitrile: acetic acid: water (4:1:1; v/v/v), without or with tetrahydrofuran (1 mL) 
(39). Different elution volumes of this mixture were used (10, 20, 30, 40 mL). 
2) butanol: acetic acid: water (4:1:1; v/v/v), without or with methanol (0.5 or 1 ml) (23). 
Different elution volumes of this mixture were used (10, 20, 30, 40 mL). 
The best results were obtained according to Space et al. (23) with some modifications. The 
SPE procedure was performed under vacuum (SPE vacuum manifold). Cellulose-packed 
column was prepared as follows: cellulose (800 mg), suspended in a solution of aqueous 
acetic acid in 1-butanol (8 mL; 1-butanol, water, acetic acid; 4:1:1; v/v/v; named butanolic 
solution), was loaded onto a column and allowed to settle. Then, it was washed with the 
same butanolic solution (2 mL) and the bed top protected by a filter disk. For free 
crosslinks extraction, urine (1mL), spiked with IS (210 pmol/mL), was mixed with an 
acidic solution (7 mL) of methanol, HCl (37%), acetic acid and 1-butanol (1:1:1:4; v/v/v/v) 
and loaded onto the cellulose-packed column. Then the column was eluted with butanolic 
solution (10 mL x 2) to eliminate all interfering fluorophores whereas the crosslinks were 
eluted with distilled water (4 mL). The obtained aqueous phase was centrifuged, the upper 
butanolic layer removed, water phase dried, the residue redissolved with aqueous HFBA 
solution (0.1 mL; 0.015 mol/L) and injected (20 μL) for HPLC analysis. 
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Method validation 
  Various analytical performance parameters need to be considered for the validation 
of the proposed method thus, three different calibration curves were prepared using pure 
synthesized primary calibrators and IS.  
 
Calibration curves: 
- Pure standard calibration curves (Curves 1): samples were prepared by adding increasing 
amounts of Pyr, D-Pyr, GluGal-Pyr, Gal-Pyr working standard solutions (0-10.5-21-52-
105-210-420-840 pmol/mL) and a constant IS amount (210 pmol/mL) to obtain a ratio 
(pmol analyte/pmol IS) corresponding to 0-0.05-0.1-0.25-0.5-1.0-2.0-4.0. Samples were 
dried and redissolved with aqueous HFBA solution (0.1 mL; 0.015 mol/L). The SPE 
procedures were omitted and samples were directly injected for HPLC analyses. 
- Urine calibration curves (Curves 2): pooled urine samples from healthy women (1 mL) 
were spiked with increasing amounts of pure working standard solutions (0-52-105-210-
420-840 pmol/mL) and with a constant IS amount (210 pmol/mL) to obtain a ratio (pmol 
compound/pmol IS) corresponding to 0-0.25-0.5-1.0-2.0-4.0. Due to the presence of Pyr, 
D-Pyr and GluGal-Pyr in endogenous amounts in urine, samples at 0.05 and 0.1 ratio 
(pmol compound/pmol IS) were omitted in contrast to Curve 1. Each urine calibration 
sample was subjected to the full SPE procedure as we reported for free and glycosylated 
crosslinks extraction.  
- Water calibration curves (Curves 3): water samples (1 ml) were added with IS and 
working standard solutions as reported for Curve 2 and then subjected to the full SPE 
procedure.  
The three calibration curves were prepared in triplicate, each sample was dried, the residue 
redissolved in aqueous HFBA solution (0.1 mL; 0.015 mol/L) and injected twice (20 μL) 
as reported for Curve 1 samples. The maximum calibration curve concentration was higher 
than 70-120% of the urine basal value of all the analytes measured, as required for 
analytical method performance (55,56). These curves were usefull to determine, for all the 
analytes, the linearity, recovery, precision, detection limit (LOD) and quantification limit 
(LOQ) of the assay. 
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-Linearity of the method 
 
For linearity calculation, least-square regression analysis was performed by plotting 
the peak area ratio (A/AIS) of each analyte to that of the IS (Y-axis) against the ratio of 
known added amounts of each analyte to that of IS (pmol compound/pmol IS) (X-axis).  
The concentrations of each analyte in urine were calculated using the parameters (slope 
and intercept) of the corresponding calibration curve. The used regression line was: Y=aX 
+ b (a: slope, b: intercept on Y axis). 
The comparison among the slopes obtained from Curve 2 and 3 was used to exclude any 
matrix effect for all the measured compounds. 
 
-Recovery (accuracy)  
 
To test the recovery of each compound from the biological matrix, peak area ratio 
(A/AIS) of urine samples (Curve 2), at low and high concentrations of analytes 
corresponding to a ratio of 0.25 (52 pmol compound/210 pmol IS) and 2.0 (420 pmol 
compound/210 pmol IS), were compared with Curve 1 samples at the same ratio 
containing the analytes at the theoretical maximum amount representing 100% recovery as 
not submitted to the SPE procedure, but directly injected.  
The percentage of analytes recovery for both low and high concentrations was calculated 
as the mean A/AIS value in urine added with primary calibrators subtracted by the mean 
A/AIS basal urine value and divided by the mean A/AIS of the known added concentrations 
of the primary calibrators directly injected and multiplied by 100. 
 
-Precision of the method 
 
Within-day and between-day precisions of the method were assessed by analysing 
Curve 1 samples seven times on the same day and once daily in seven consecutive days, 
respectively. The precision of the method is reported as percentage of coefficient of 
variation (CV %), calculated at two concentrations of all the analytes corresponding to a 
ratio of 0.25 and 2.0 as those used for recovery. The CV% was calculated according to the 
formula: SD/mean values x 100, where SD is the standard deviation of the response. 
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-Limit of detection and limit of quantification 
 
The limit of detection (LOD) and the limit of quantification (LOQ) for each 
analyte, expressed as a concentration (pmol/mL), obtained by injecting Curve 1 sample at 
0.1 ratio (21 pmol compound/210 pmol IS) once daily in seven different days, were 
estimated based on the standard deviation of the response and the slope of calibration 
Curve 1. The formulas 3.3 (SD/S) and 10 (SD/S) were used for LOD and LOQ, 
respectively, where SD is the standard deviation of the response and S is the slope of the 
analyte corresponding calibration curve. 
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Acid hydrolysis conditions  for total Pyr and D-Pyr evaluation in urine 
To find the best conditions for the hydrolysis reaction, the following variables were 
tested: 
- HCl final concentration: 6 mol/L and 3 mol/L 
 - Hydrolysis time: 2, 4, 6, 8, 12 and 15 hours 
The hydrolysis reactions, for water and urine pool samples (1 mL), were carried out using 
sealed Pyrex ampoules in an heating block system at 110°C. 
1) Water sample hydrolysis was performed to evaluate and confirm the chemical stability 
of both internal standard and primary calibrators to the drastic used conditions and to 
evidence the desappearance in time of the glycosylated crosslinks due to their complete 
hydrolysis.  
Water samples (1 mL) were prepared by adding Pyr and D-Pyr, both at 210 pmol/mL, or 
GluGal-Pyr and Gal-Pyr, both at 210 pmol/mL, and IS (210 pmol/mL) (ratio 1:1:1 for 
crosslinks and IS).  
Water samples were hydrolyzed in the presence of two different HCl concentrations 
obtained by adding HCl 37% (1 mL) to water (1 mL) (HCl final concentration: 6 mol/L) or 
HCl (6 mol/L) to water (1 mL) (HCl final concentration: 3 mol/L). 
Water samples were hydrolyzed for 2, 4, 6, 10, 15 h and then submitted to the complete 
work-up.  
2) Pooled urine samples (1 mL), added with IS (210 pmol/mL), were hydrolyzed under the 
different indicated conditions. At the end of the hydrolysis reaction, urine samples were 
centrifuged and the precipitated proteins separated from supernatant. The obtained 
supernatant was loaded onto SPE column and submitted to the complete work-up as 
reported for free crosslinks extraction and for HPLC analysis.  
The chemical stability of the IS to the hydrolysis conditions, was also tested by adding the 
IS to urine samples (n=3) both before or immediately after the hydrolysis reaction done 
before the protein separation by centrifugation.   
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RESULTS AND DISCUSSION 
 
Free and glycosylated crosslinks extraction from urine and their HPLC-fluorescence 
evaluation 
Due to the extreme polarity of Pyr, D-Pyr and glycosylated crosslinks, several 
conditions for their HPLC separation and their solid-phase extraction from biological 
matrices have been reported in literature (22,23,39).  
Our preliminary studies, carried out using working primary calibrators standard solutions, 
were performed to achieve the best HPLC crosslinks separation. Two HPLC columns were 
tested: Nucleosil 100 RP C18 and Reprosil-Pur Basic C18, together with various mobile 
phases (H2O:ACN and H2O:MeOH) added with two ion-pairing agents, 
pentafluoropropionic acid (PFPA) or  heptafluorobutyric acid (HFBA), necessary to retain 
the positively charged crosslinks on HPLC column. The hydrophobicity of the ion-pairing 
agent and the composition of mobile phase (pH, organic solvent) condition the retention 
times and the resolution of the pyridinium crosslinks from each other and from interfering 
fluorophores present in the biological matrix.  
The best HPLC peaks resolution and run time of the analysis were obtained in isocratic 
condition using the Reprosil-Pur Basic C18 column with aqueous HFBA solution (0.015 
mol/L):acetonitrile (88:12; v:v) as mobile phase at 0.6 mL/min flow rate (λex 295 nm and 
λem 400 nm).   
Studies were also performed for urine crosslinks purification by solid phase extraction 
(SPE) comparing different reported conditions (23,39). Usually, most of fluorescent 
undesirable compounds is extracted from urine on a cellulose column by a butanolic 
solution whereas crosslinks are removed by water. However, being butanol miscible in 
water, there is the possibility of an incomplete butanolic phase separation from water, 
causing the presence of impurities in the crosslinks extract. Thus, the addition of methanol 
(23) or tetrahydrofuran (39) has been proposed. Our results showed cleaner extracts and 
higher crosslinks recovery by the addition of methanol to the acidic solution used to load 
the urine samples on the SPE column.  
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The typical isocratic ion-paired reversed-phase HPLC chromatogram for free and 
glycolylated crosslinks separation in the best tested conditions is reported in Fig.5. The 
chromatogram of a pure synthesized primary calibrators mixture added with IS (pannel A) 
shows good resolution of all the compounds as distinct peaks. By comparing the 
chromatograms obtained injecting an extract of the pooled women urine added with IS 
(pannel B) or without IS (pannel C), the absence in urine (pannel C) of a peak at the 
retention time of that of the selected IS suggests its possible use for this purpose. 
Moreover, it is possible to note the absence of a peak at the retention time of the pure 
synthesized Gal-Pyr in women urines (pannels B and C). 
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Fig.5 Reversed-phase HPLC chromatograms 
 
 
(A) pure synthesized primary calibrators mixed at ratio 1:1 with IS (210 pmol/mL) and 
directly injected. (B) pooled women urine added with IS (210 pmol/mL) before SPE 
extraction or (C) without the addition of IS.  
Peak 1, GluGal-Pyr; peak 2, Gal-Pyr; peak 3, Pyr; peak 4, D-Pyr; peak 5, IS. The 
concentrations in pooled women urine were: GluGal- Pyr (91 pmol/mL), Gal- Pyr (n.q.; 
<LOQ), Pyr (233 pmol/mL) and D-Pyr (43 pmol/mL). 
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Performance of the assay 
The performance of the assay was tested in samples not submitted to the hydrolysis 
reaction. 
 
-  Linearity 
Fluorescent-HPLC responses were linear for Pyr, D-Pyr, Gal-Pyr, GluGal-Pyr up to 
1680 pmol/mL (336 pmol injected) corresponding to a ratio of 8 (pmol compound/pmol 
IS) higher than ratio of 4 (170 pmol injected), here reported for the calibration curves, 
being the last ratio over the pooled urine concentration.  
Mean values for linear regression parameters of the three calibration curves are presented 
in Table 3.   
The good linearity of the assay is confirmed by the coefficients of correlation (R
2
)  0.99 
for all the tested compounds for the three types of calibration curves. The biological matrix 
does not interfere on the determination of all the analytes, as evidenced by the similar 
slopes in all the calibration curves. The low Gal-Pyr intercept indicates the absence of this 
compound in pooled women urine, whereas that of GluGal-Pyr, even if 3-fold lower than 
that of Pyr, suggests a contribution of this glycosylated-Pyr to the total Pyr amounts.      
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Table 3. Linearity data: Calibration curves. 
 
 
 Pyr D-Pyr Gal-Pyr GluGal-Pyr 
CURVE 1     
Slope  0.897 (0.016) 0.926 (0.040) 0.867 (0.028) 0.889 (0.014) 
Intercept  0.012 (0.008) 0.030 (0.023) 0.022 (0.017) 0.019 (0.013) 
R
2 a
 0.999 0.999 0.998 0.998 
Sy/x 
b
 0.023 0.099 0.020 0.057 
CURVE 2     
Slope  0.887 (0.033) 0.928 (0.014) 0.816 (0.012) 0.805 (0.024) 
Intercept  0.981 (0.046) 0.159 (0.015) 0.027 (0.014) 0.323 (0.022) 
R
2 a
 0.997 0.998 0.997 0.997 
Sy/x 
b
 0.069 0.052 0.086 0.073 
CURVE 3     
Slope  0.882 (0.014) 0.914 (0.009) 0.820 (0.017) 0.833 (0.013) 
Intercept  0.027 (0.016) 0.044 (0.024) 0.023 (0.015) 0.024 (0.020) 
R
2 a
 0.999 0.999 0.998 0.998 
Sy/x 
b
 0.022 0.033 0.017 0.040 
 
 
 
CURVE 1: pure standards mixture samples were directly injected in HPLC-
fluorescence. CURVE 2: pooled women urine samples and CURVE 3: water 
samples were submitted to SPE before HPLC-fluorescence analysis.  
Values are reported as mean (±SD). 
a 
Correlation coefficients; 
b
 Standard deviation 
of residuals. Each calibration curve was prepared in triplicate as indicated in 
Materials and Methods and each sample twice injected. 
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Analytical characteristics of the method 
- Precision  
The use of the internal standard allows to determine all the compounds of interest with a 
good analytical precision (Table 4). For all compounds, the percentage of coefficients of 
variation (CV%) are lower than 4.86 % and 5.11%, for both within- and between-day 
analysis, respectively, at the lower (52 pmol/mL) and the higher (420 pmol/mL) tested 
concentrations. 
 
Table. 4. Analytical characteristics of the method: precision of the assay. 
 
 
 
 
 
 within-day (n=7) 
%CV 
between-day (n=7) 
%CV 
compounds ratio 0.25 
a
 ratio 2.0
 a
 ratio 0.25
 a
 ratio 2.0
 a
 
     
Pyr 4.86 (0.29) 3.07 (1.62) 2.52 (0.49) 2.79 (2.30) 
D-Pyr 4.86 (0.29) 2.94 (1.62) 3.71 (0.22) 3.96 (2.15) 
Gal-Pyr 4.57 (0.27) 1.03 (0.64) 3.68 (0.23) 3.91 (2.40) 
GluGal-
Pyr 
4.35 (0.26) 1.56 (0.93) 5.11 (0.31) 3.09 (1.79) 
 
 
 
 
a
 Pooled urine samples were spiked with all primary calibrators at 52 or 420 
pmol/mL and IS (210   pmol/mL) to obtain the ratio 0.25 or 2.0 (calibrator/IS), 
respectively (samples from Curve 2). 
Results are reported as mean values %CV (SD). The %CV was calculated 
according the formula: SD/mean values x 100, where SD is the standard 
deviation of  the response. 
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- Recovery, LOD and LOQ 
The results reported in Table 5 indicate a recovery higher than 80% for all the 
studied compounds, at both the lower and higher amounts injected. The lowest determined 
limit of quantification (LOQ) for Pyr shows the possibility of its evaluation in urine at the 
concentration of 10.85 pmol/mL, D-Pyr at 22.81 pmol/mL, Gal-Pyr 28.25 pmol/mL and 
GluGal-Pyr at 23.43 pmol/mL.       
 
 
Table. 5. Analytical characteristics of the method: recovery, LOD and LOQ. 
 
 Recovery 
% 
LOD 
(pmol/mL) 
LOQ 
(pmol/mL) 
compounds ratio 0.25 
a
 ratio 2.0
 a
 ratio 0.1
 b
 ratio 0.1
 b
 
     
Pyr 95.1 (4.3) 97.1 (4.2) 3.58 10.85 
D-Pyr 85.9 (5.6) 91.9 (3.5) 7.53 22.81 
Gal-Pyr 81.8 (5.2) 94.4 (5.2) 9.35 28.25 
GluGal-Pyr 88.5 (8.4) 95.7 (1.3) 7.73 23.43 
 
a
 Pooled women urine samples were spiked with all primary calibrators at 52 or 420 
pmol/mL and IS (210 pmol/mL) to obtain the ratio 0.25 or 2.0 (calibrator/IS), respectively 
(samples from Curve 2).   
Results are reported as mean recovery % (SD). 
b
 Samples (Curve1) at 0.1 ratio (21 pmol/210 pmol IS). Each sample was injected once 
daily in 7 different days.  
 
The limit of detection (LOD) and limit of quantification (LOQ) were calculated by 
3.3(SD/S) and 10(SD/S) formula, respectively. SD: standard deviation of amounts (pmol). 
S: slope (mean) of calibration Curve 1.  
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Hydrolysis conditions for total Pyr and D-Pyr evaluation 
Total urinary crosslinks are routinely assayed after overnight hydrolysis in the 
presence of HCl 6 mol/L (final concentration) at 110°C. However, these drastic conditions 
could affect the chemical structure of the pyridinium crosslinks and of our selected internal 
standard. In fact, stereoisomers or epimers formation under hydrolysis has been described 
using aminoacids (11,18).  
To search for the best hydrolysis conditions for Gal-Pyr and GluGal-Pyr, and to confirm 
the chemical stability of Pyr, D-Pyr and of the selected internal standard, different reaction 
times (2, 4, 6, 10, 15 h) were first tested in water samples.  
According to others (22), we found that after two hours at 110°C, pure Gal-Pyr and 
GluGal-Pyr, added to water samples, were totally hydrolyzed. After all the selected 
reaction times, also the chemical stability of pure Pyr, D-Pyr and IS in water samples, was 
confirmed by the recovery of Pyr/IS and D-Pyr/IS at the same ratio as that added to the 
water samples before the hydrolysis reaction.  
When pooled women urine were hydrolyzed in the presence of HCl 3 mol/L, the obtained 
Pyr and D-Pyr amounts were about the 90% of those formed in the presence of HCl 6 
mol/L.  
Moreover, when pooled women urine were hydrolyzed in the presence of HCl 6 mol/L for 
longer time, Pyr and D-Pyr amounts increased, but after 10 and 15 h, fluorophores 
compounds, less polar than GluGal-Pyr, appeared in the HPLC chromatogram (but not in 
that of children). 
Thus, we decided to perform the hydrolysis in the presence of HCl 6 mol/L for 6 h, to 
avoid the formation of these interfering compounds that could compromise the HPLC 
resolution of the compounds of interest. This was a good compromise that allowed a 
satisfactory analysis of Pyr and D-Pyr, even if the final crosslinks amount in urine resulted 
10% lower than that determined after longer reaction time.  
At these selected hydrolysis conditions, the chemical IS stability was confirmed by the 
same total Pyr and D-Pyr amounts measured in pooled women urine when IS was added 
before or immediately after the hydrolysis reaction. 
Total Pyr and D-Pyr amounts in pooled healthy women urine (n=7) account for 477.11±8.6 
and 91.03±6.3 pmol/mL, respectively (mean±SD of six injections). 
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Free, glycosylated and total crosslinks evaluation in healthy women and children  urine 
We tested the feasibility of the studied method evaluating free, glycosylated and 
total crosslinks in urine of healthy women and girls. 
To minimize the biologic variability, due to age and gender, only women (30-40 years-old) 
were selected to compare our results with those reported by others in adult healthy groups. 
Girls were enrolled as, being in growing age and having a bone remodelling rate extremely 
high, their physiological levels of urine collagen crosslinks in this stage of the life 
appeared of particular interest to be compared with those of an omogeneous group of pre-
menopausal women. Moreover, girls were selected as, except some authors (27,42,54), D-
Pyr, hydroxylysine (Hyl), galactose-Hyl and glucose-galactose-Hyl, are usually measured 
as bone and collagen turnover markers in children (35-38) and GluGal-Pyr amounts in 
children are not available. In particular, GluGal-Pyr has been identified, but not measured, 
by Roth et al. (27) in adult controls and children urines, suggesting the possibility for 
GluGal-Pyr to be formed not only by synovium, as reported by Gineyts et al. (32), but also 
by other tissues. 
Due to the crosslinks variable dilution in urine, it is common practice to adjust urinary 
values according to a reference parameter such as urine creatinine amounts. However, as 
reported (26,55), many endogenous (age, gender, renal insufficiency, hydration state, 
changing in muscle mass, circadian rhythm) and exogenous factors (life style, dietary 
intake) migh affect creatinine concentration together with the day-time for urine collection 
(morning or 24 h urine) and with the analytical methods for creatinine measurement 
(26,34,39,55). Thus, creatinine correction is far from satisfactory as its excretion over 24 h 
can vary not only between individuals but also within individuals. 
Even if the 24 h urine offers the advantage of allowing a mean of daily urine excretion, its 
collection is complex expecially when children are involved, and first-morning urine are 
often used for crosslinks measurements.   
As proposed by some authors (34), we reported our crosslinks results both as molar 
concentrations (pmol/mL urine), and corrected by urine creatinine level (nmol/mmol 
creatinine), measured in clinical laboratory, to compare our values with those reported by 
others (16,27,28,32,39).  
The results reported in Table 3, show a significant increase in Pyr, D-Pyr (both free and 
total) and GluGal-Pyr in girls respect to women. Gal-Pyr was under its lowest 
quantification limit (LOQ≥28.25 pmol/mL) or absent in women, while it was quantifiable 
in girls with values significantly lower in 5-6 year-old girls respect to the 9-10 year-old 
35 
 
ones. The observed higher Pyr and D-Pyr concentrations in girls urine respect to women 
were expected, considering the high skeletal growth velocity and the rapid bone turnover 
during childhood growth. Similarly, by comparing the fractions of free to total crosslinks 
forms, the significantly higher percentages of both free Pyr/total Pyr and free D-Pyr/total 
D-Pyr in girls than in women might reflect both an higher availability of free Pyr and D-
Pyr to form crosslinks in children and an increased collagen turnover rather than bone 
turnover alone.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
36 
 
Table 6. Free, glycosylated and total crosslinks amounts in healthy women and girls urine. 
 
 Women  
(n=20) 
(33.9±7.1 y) 
Girls 
      (n=10)              (n=10)  
 ( 5 . 8 ±0.8 y )  ( 9 . 6 ±0.5 y )          
Compounds 
f Pyr 
(pmol/mL) 
231.3* (45.5) 
[172-282] 
989.7 (166.7)       1026.0 (73.9) 
[799-1151]        [962-1107] 
f Pyr/Crea 
(nmol/mmolCr) 
  33.8* (6.6) 
[24-39] 
111.8 (19.9)          118.0 (8.8) 
[90-131]            [108-127] 
f D-Pyr 
(pmol/mL) 
  41.7* (9.3) 
[36-55] 
180.3 (24.5)           214.0 (41.4) 
    [159-200]            [171-263] 
f D-Pyr/Crea 
(nmol/mmolCr) 
   6.1* (1.5) 
[4.8-7.6] 
  20.4 (3.2)           24.7 (3.9) 
      [17-23]           [21-30] 
f Pyr/f D-Pyr    5.7  (1.0) 
[4.5-6.5] 
    5.5 (0.6)             4.9
#
 (0.8) 
     [5.0-6.3]            [4.2-5.9] 
t Pyr 
(pmol/mL) 
468.5* (121.8) 
[307-612] 
1394.5 (261.2)  1497.4 (155.7) 
  [1140-1743]       [1347-1663] 
t Pyr/Crea 
(nmol/mmolCr) 
  77.7* (7.9) 
 
156.0 (29.4)       171.9 (20.6) 
 
t D-Pyr 
(pmol/mL) 
  84.5* (23.9) 
    [50-112] 
275.3 (55.2)        239.9 (55.5) 
[210-333]          [277-340] 
t D-Pyr/Crea 
(nmol/mmolCr) 
 12.4* (3.9) 
    [7-16] 
  30.7 (5.9)            37.7 (5.5) 
  [23-37]               [33-46] 
t Pyr/t D-Pyr   5.7 (1.0) 
    [4.3-6.7] 
    5.1 (0.6)             4.6 (0.5) 
    [4.4-5.6]            [4.1-5.2] 
% f Pyr/t Pyr   50.38* (1.0)   71.9 (11.9)         68.5 (4.4) 
 
% f D-Pyr/t D-Pyr   51.3° (12.9)   67.1 (13.2)         65.1 (5.0) 
 
GluGal-Pyr 
(pmol/mL) 
90.3* (15.0) 
[76-105] 
226.9 (27.4)       196.3 (44.1) 
  [201-249]            [153-246] 
GluGal-Pyr/Crea 
(nmol/mmolCr) 
 13.2* (2.0) 
[11-16] 
  25.6 (3.5)           22.2 (4.0) 
      [22-28]              [19-27] 
Gal-Pyr 
(pmol/mL) 
n.q.   41.1 (8.2)           53.0 (11.5) 
      [33-50]              [42-65] 
Gal-Pyr/Crea 
(nmol/mmolCr) 
n.q.    4.6 (0.9)             6.1 (1.4) 
    [3.7-5.6]              [4.7-7.5] 
 
Results are reported as mean (±SD) and as median [10th-90th] percentile range. 
f: free; t: total; Crea: creatinine; n.q.: not quantifiable (≥LOQ).  
*p<0.0001 vs girls; °p<0.020 vs girls; 
#
p<0.01 vs women. The significant differences were 
evaluated by Student’s t-test. 
 
 
37 
 
 
It is important to note that both GluGal-Pyr and Gal-Pyr have never been evaluated 
in children. GluGal-Pyr is considered by some authors (28,32) an useful marker of 
synovium degradation as its  
increase was observed in subjects affected by rheumatoid arthritis. However, the present 
study shows that GluGal-Pyr is present in urine of healthy women and in higher amounts 
in children, all with no apparent cartilage problems. Our findings agree with results 
reported by Roth et al (27) who identified, but not measured, GluGal-Pyr in the HPLC 
chromatogram of adult controls and of eleven-old adolescent urines. Thus, as suggested by 
Roth (27), synovium cannot be the only tissue originating GluGal-Pyr and this 
glycosylated compound cannot be a specific marker only for synovium degradation. 
Our results seem to evidence a role for both GluGal-Pyr and Gal-Pyr in bone and collagen 
formation during children growth. In fact, Gal-Pyr, which is under our detection limit or 
absent in women urine, is present in children, and GluGal-Pyr is higher in children than in 
women. Since the urinary excreted GluGal-Pyr in children urine is 6-fold higher respect to 
Gal-Pyr amounts, we might speculate that Gal-Pyr could be the substrate for the Pyr 
disaccharide formation.  
Pyridinoline derives from hydroxylysine (Hyl) by chemical reactions and is transformed 
into its glycosylated forms by specific transferase. It has been reported that for the HyL 
crosslinks formation, the GluGal-Hyl is assembled in a stepwise manner through the action 
of specific galactosyl and glucosyl transferase and that the presence of galactose linked to 
hydroxylysine (Gal-Hyl) represents the good substrate to form the disaccharide units by 
glucosyl transferase (5,56). As GluGal-Pyr and Gal-Pyr derive from Pyr by reaction with 
specific transferase, there is the possibility for GluGal-Pyr to be formed through the 
preformed Gal-Pyr (57).  
Hyl, GluGal-Hyl and Gal-Hyl, are often used as bone markers for children bone health 
studies (35-38); they form crosslinks in the newly generated collagen (10,36), whereas 
pyridinium forms crosslinks in the mature collagen. GluGal-Hyl and Gal-Hyl are excreted 
in urine of 6-7 years-old girls in the same concentrations (36), whereas our measured 
GluGal-Pyr is 6-fold higher respect to Gal-Pyr amounts. Moreover, it has been reported 
that GluGal-Hyl reflects skin collagen metabolism better than bone metabolism (6,36), 
whereas Gal-Hyl that of bone (38). Thus, the evaluation of both GluGal-Pyr and Gal-Pyr 
might increase the knowledge on bone formation and resorption during children growth 
together with hydroxilysine crosslinks. 
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The biological importance of collagen glycosylation on the stability of the triple-helical 
structure and on the mechanical properties of bone has been recently reported (57,58). 
Thus, the evaluation of GluGal-Pyr and Gal-Pyr could be useful also to study pathological 
conditions characterized by modified activity of galactosyl- and glucosyl-transferase, the 
enzyme involved in the collagen glycosylation.  
 
 
When we compare our free, glycosylated and total crosslinks amounts, measured in woman 
and girls urine, with the wide range of values reported by others (Tab.7), it appears evident 
the very little data concerning both free and glycosylated crosslinks both in adult subjects 
and in children.   
Our free D-Pyr amounts in women urines are in agreement with the results reported by 
some authors (36,38,54), but contrast with others (22,16,39). On one hand, our total 
crosslinks amount is in agreement with one obtained by some authors (15,41,42), but on 
the other hand it is higher respect to others (32) who carried out the hydrolysis reaction in 
the presence of NaOH instead of HCl. In fact, it has been reported that about less than 50% 
of the total crosslinks are recovered under basic conditions respect to those obtained after 
acidic conditions (22). Also for GluGal-Pyr, our values are 2-fold higher respect to those 
reported in controls urine by Garnero et al. (28,32), the only authors measuring this 
glycosylated pyridinium derivative.  
These discrepancies might be attributable to control groups, often not well matched for age 
and gender, but more likely to the lack in their method of an adequate internal standard and 
of pure primary calibrators.  
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Table 7. Literature reference intervals for urinary crosslinks  in adult and children urine.  
 
Ref. Sex Age  
(years) 
ADULT 
Pyr/Crea 
(nmol/mmol) 
Free            
Total 
D-Pyr/Crea 
(nmol/mmol) 
Free           Total 
Pyr 
(nmol/L) 
Free       
Total 
D-Pyr 
(nmol/L) 
Free     Total 
GluGal-Pyr/ 
Crea 
(nmol/mmol) 
Gal-Pyr/ 
Crea 
(nmol/mmol) 
[22]   14-63 14-181 4-6 5-106 ---- ---- ---- ---- ---- ---- 
[16] (F) 24-50 10 45 2 9 ----  ----  ---- ---- 
[32]  30-40 ---- 28±4 ---- 6±1 ---- ---- ---- ---- 4±1 ---- 
[15]   ---- 231-365 ---- 40-60 ---- ---- ---- ---- ---- ---- 
[6]   ---- ---- ---- ---- ---- 115-
150 
---- 45-70 ---- ---- 
[39]   ---- ---- ---- ---- 51 222 19 53 ---- ---- 
[41] (F)  ---- 49 ---- 7 ---- ---- ---- ---- ---- ---- 
[54] (M+F)  16±6 22±12 6±5 8±6 ---- ---- ---- ---- ---- ---- 
[42] (F) 30-39 ---- 44±12 ---- 9±2 ---- ---- ---- ---- ---- ---- 
             
Our 
results 
(F) 27-45 24-38 45-82 5-8 7-16 172-
282 
307-
612 
36-55 50-
112 
11-16 n.d 
  CHILDREN           
[38]  4-10 ---- 79-210 ----- 20-66 ---- ---- ---- ---- ---- ---- 
  10-12 ---- 79-387 ----- 25-104 ---- ---- ---- ---- ---- ---- 
[36]  8-11 ----  ---- 14-23 ---- ---- ---- ---- ---- ---- 
[42] (M+F) 6-10 116±30 189±72 28±10 63±26 ---- ---- ---- ---- ---- ---- 
[54]  5-8 ---- 343±207 ---- 77±50 ---- ---- ---- ---- ---- ---- 
  8-11 ---- 275±122 ---- 51±24 ---- ---- ---- ---- ---- ---- 
             
Our 
results 
(F) 5-6 90-131 128-193 17-23 23-37 799-
1151 
1140-
1743 
159-
200 
210-
333 
22-28 3.7-5.6 
  9-10 108-
127 
148-195 21-30 33-46 962-
1107 
1347-
1663 
171-
263 
277-
340 
19-27 4.7-7.5 
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Herein we set-up and validate the first HPLC-fluorescence method for the simultaneous 
quantification of free and glycosylated crosslinks in urine, which uses a superior unnatural 
homologue of D-Pyr as internal standard. The specificity of the method is guaranteed by 
the use of the internal standard and of pure synthesized primary calibrators of Pyr, D-Pyr, 
Gal-Pyr and GluGal-Pyr. Our method demonstrates to have good linearity, recovery, 
precision, LOD and LOQ for all compounds.  
The measurement of consisting amounts of GluGal-Pyr in both women and children urine 
and few but detectable Gal-Pyr amounts only in girls confirms the importance for free and 
glycosylated crosslinks quantification. In fact, whereas the assessment of total urinary D-
Pyr, found only in bone and dentine, provides an index of bone resorption, the evaluation 
of total Pyr, found in bone, cartilage and synovium, does not allow to distinguish among 
the degradation of bone, synovium or joint, and between free and glycosylated-Pyr.  
Thus, the evaluation of both free, glycosylated and total crosslinks excretion in urine might 
provide more information on bone and collagen catabolism, particularly in pathological 
conditions and in monitoring both the disease progression and the response to medical 
treatment.  
Furthermore, since recently it has been suggested a biological importance of collagen 
glycosylation on the bone structure stability and on the mechanical properties, the 
analytical method herein reported could be useful also to study pathological conditions 
characterized by modified activity of the enzymes involved in the collagen glycosylation 
(i.e. galactosyl- and glucosyltransferase). 
Thus, our results stimulate additional researches to clarify the origin and the meaning of 
these glycosylated collagen crosslinks particularly in children and their possible variation 
under pathological conditions.  
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